{"id":18489,"date":"2021-07-16T08:09:19","date_gmt":"2021-07-16T12:09:19","guid":{"rendered":"https:\/\/medicarereport.org\/?p=18489"},"modified":"2021-07-16T08:09:19","modified_gmt":"2021-07-16T12:09:19","slug":"unitedhealth-ceo-unknowns-of-biogen-alzheimers-drug-mean-insurer-wont-yet-cover-it","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=18489","title":{"rendered":"UnitedHealth CEO: Unknowns of Biogen Alzheimer&#8217;s drug mean insurer won&#8217;t yet cover it"},"content":{"rendered":"<p>(By\u00a0Nick Moran for <em>Becker&#8217;s Hospital Review<\/em>)<\/p>\n<p>UnitedHealth Group CEO Andrew Witty said the payer needs to see more data on Aduhelm, Biogen&#8217;s controversial Alzheimer&#8217;s drug, before it will cover it.\u00a0 Continue reading the article <a href=\"https:\/\/www.beckershospitalreview.com\/payer-issues\/unitedhealth-ceo-unknowns-of-biogen-alzheimer-s-drug-mean-insurer-won-t-yet-cover-it.html\">here&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2019\/12\/health-insurance.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-14818\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2019\/12\/health-insurance-300x204.png\" alt=\"\" width=\"300\" height=\"204\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2019\/12\/health-insurance-300x204.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2019\/12\/health-insurance.png 534w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<pre><strong>Notice:<\/strong> The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org<\/pre>\n","protected":false},"excerpt":{"rendered":"<p>(By\u00a0Nick Moran for Becker&#8217;s Hospital Review) UnitedHealth Group CEO Andrew Witty said the payer needs to see more data on<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26,42,9,15],"tags":[],"class_list":["post-18489","post","type-post","status-publish","format-standard","hentry","category-alzheimersdementia","category-employer-healthcare","category-medicare-advantage","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/18489","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=18489"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/18489\/revisions"}],"predecessor-version":[{"id":18490,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/18489\/revisions\/18490"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=18489"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=18489"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=18489"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}